Literature DB >> 9058659

Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid.

G Partsch1, G Steiner, B F Leeb, A Dunky, H Bröll, J S Smolen.   

Abstract

OBJECTIVE: To investigate the potential role of cytokines in psoriatic arthritis (PsA) by assessing the profiles of the proinflammatory cytokines in synovial fluid (SF) of PsA in comparison with rheumatoid arthritis (RA) and osteoarthritis (OA).
METHODS: Levels of tumor necrosis factor-alpha (TNF-alpha), interleukin 1 (IL-1), IL-6, and IL-8 were measured in SF using ELISA.
RESULTS: Levels of TNF-alpha, IL-1beta, and IL-8 were significantly higher in PsA SF than in OA SF, although lower than in RA SF. No difference was detected in the IL-6 levels between PsA and RA SF, both of which were much higher than in OA SF.
CONCLUSION: The pattern of expression of proinflammatory cytokines seen in PsA is similar to that in RA. Since PsA is also a destructive arthropathy, cytokines, in particular TNF-alpha and IL-1, may be principle factors in joint destruction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9058659

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  62 in total

Review 1.  Ankylosing spondylitis: introductory comments on its diagnosis and treatment.

Authors:  M A Khan
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

2.  TNFalpha therapy in psoriatic arthritis and psoriasis.

Authors:  P Mease
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

Review 3.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

Review 4.  Role of chemokines, innate and adaptive immunity.

Authors:  Kurt A Zimmerman; Katharina Hopp; Michal Mrug
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

5.  Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.

Authors:  A Kavanaugh; G G Krueger; A Beutler; C Guzzo; B Zhou; L T Dooley; P J Mease; D D Gladman; K de Vlam; P P Geusens; C Birbara; D G Halter; C Antoni
Journal:  Ann Rheum Dis       Date:  2006-11-17       Impact factor: 19.103

6.  Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behçet's disease, familial Mediterranean fever, rheumatoid arthritis, and osteoarthritis.

Authors:  Hakan Erdem; Salih Pay; Muhittin Serdar; Ismail Simşek; Ayhan Dinç; Uğur Muşabak; Aysel Pekel; Mustafa Turan
Journal:  Rheumatol Int       Date:  2004-11-03       Impact factor: 2.631

Review 7.  Genetic factors in psoriatic arthritis.

Authors:  Eleanor Korendowych; Neil McHugh
Journal:  Curr Rheumatol Rep       Date:  2005-08       Impact factor: 4.592

8.  Ectopic lymphoid neogenesis in psoriatic arthritis.

Authors:  Juan D Cañete; Begoña Santiago; Tineke Cantaert; Raimon Sanmartí; Antonio Palacin; Raquel Celis; Eduard Graell; Beatriz Gil-Torregrosa; Dominique Baeten; José L Pablos
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

Review 9.  Altered bone remodeling in psoriatic arthritis.

Authors:  Kofi A Mensah; Edward M Schwarz; Christopher T Ritchlin
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

Review 10.  Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective.

Authors:  David Kane; Oliver FitzGerald
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.